Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD

Seminars in Liver Disease

Volumn 35, Issue 3, 2015, Pages 250-261

  Vacca, Michele ^a,b   Allison, Michael ^c   Griffin, Julian L ^a,b   Vidal Puig, Antonio ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

carbohydrate response element binding protein; insulin resistance; mitochondrial dysfunction; peroxisome proliferator activated receptors; sterol regulatory element binding protein 1

Indexed keywords

ADIPONECTIN; BINDING PROTEIN; FAT; FATTY ACID; GLUCOSE; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUGAR; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; INSULIN;

ADIPOSE TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; DIET; DISEASE COURSE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIPOTOXICITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METABOLISM; LIVER MITOCHONDRION; METABOLIC REGULATION; MOLECULAR SENSOR; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIENT; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TRANSPORT; ANIMAL; BLOOD; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK FACTOR;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; DISEASE PROGRESSION; FATTY ACIDS; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MITOCHONDRIA, LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK FACTORS;

EID: 84941910467     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1562945     Document Type: Article

References (125)

1. Matteoni C. A., Younossi Z. M., Gramlich T., Boparai N., Liu Y. C., McCullough A. J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology: 1999; 116 6 1413 1419
2. Cohen J. C., Horton J. D., Hobbs H. H. Human fatty liver disease: old questions and new insights. Science: 2011; 332 6037 1519 1523
3. Adams L. A., Angulo P., Lindor K. D. Nonalcoholic fatty liver disease. CMAJ: 2005; 172 7 899 905
4. Browning J. D., Szczepaniak L. S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology: 2004; 40 6 1387 1395
5. Browning J. D., Horton J. D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest: 2004; 114 2 147 152
6. Korenblat K. M., Fabbrini E., Mohammed B. S., Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology: 2008; 134 5 1369 1375
7. Postic C., Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab: 2008; 34 6 Pt 2 643 648
8. He W., Barak Y., Hevener A., et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A: 2003; 100 26 15712 15717
9. Medina-Gomez G., Gray S. L., Yetukuri L., et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet: 2007; 3 4 e64
10. Rodriguez-Cuenca S., Carobbio S., Vidal-Puig A. Ablation of Pparg2 impairs lipolysis and reveals murine strain differences in lipolytic responses. FASEB J: 2012; 26 5 1835 1844
11. Kempinska-Podhorodecka A., Krawczyk M., Klak M., et al. Healthy PNPLA3 risk allele carriers present with unexpected body fat composition. A study of one thousand subjects. J Gastrointestin Liver Dis: 2014; 23 1 33 37
12. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology: 2012; 142 4 711 725.e6
13. Virtue S., Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome-an allostatic perspective. Biochim Biophys Acta: 2010; 1801 3 338 349
14. Musso G., Cassader M., De Michieli F., Rosina F., Orlandi F., Gambino R. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology: 2012; 56 3 933 942
15. Kraegen E. W., Clark P. W., Jenkins A. B., Daley E. A., Chisholm D. J., Storlien L. H. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes: 1991; 40 11 1397 1403
16. Rolo A. P., Teodoro J. S., Palmeira C. M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med: 2012; 52 1 59 69
17. Pessayre D., Fromenty B. NASH: a mitochondrial disease. J Hepatol: 2005; 42 6 928 940
18. Sanyal A. J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology: 2001; 120 5 1183 1192
19. Fan C. Y., Pan J., Usuda N., Yeldandi A. V., Rao M. S., Reddy J. K. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem: 1998; 273 25 15639 15645
20. Sanyal A. J., Chalasani N., Kowdley K. V., et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
21. Donnelly K. L., Smith C. I., Schwarzenberg S. J., Jessurun J., Boldt M. D., Parks E. J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest: 2005; 115 5 1343 1351
22. Adiels M., Taskinen M. R., Packard C., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia: 2006; 49 4 755 765
23. Fabbrini E., Mohammed B. S., Magkos F., Korenblat K. M., Patterson B. W., Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology: 2008; 134 2 424 431
24. Horton J. D., Shimano H., Hamilton R. L., Brown M. S., Goldstein J. L. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest: 1999; 103 7 1067 1076
25. Duivenvoorden I., Teusink B., Rensen P. C., Romijn J. A., Havekes L. M., Voshol P. J. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes: 2005; 54 3 664 671
26. Lee H. Y., Birkenfeld A. L., Jornayvaz F. R., et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology: 2011; 54 5 1650 1660
27. Caron S., Verrijken A., Mertens I., et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol: 2011; 31 3 513 519
28. Chen M., Breslow J. L., Li W., Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res: 1994; 35 11 1918 1924
29. Schenk S., Saberi M., Olefsky J. M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest: 2008; 118 9 2992 3002
30. Mittendorfer B., Magkos F., Fabbrini E., Mohammed B. S., Klein S. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity (Silver Spring): 2009; 17 10 1872 1877
31. Anstee Q. M. Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. Liver Int: 2011; 31 4 440 442
32. Miyazaki M., Flowers M. T., Sampath H., et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab: 2007; 6 6 484 496
33. Bergheim I., Weber S., Vos M., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol: 2008; 48 6 983 992
34. Feldstein A. E., Canbay A., Guicciardi M. E., Higuchi H., Bronk S. F., Gores G. J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol: 2003; 39 6 978 983
35. Kennedy A. R., Pissios P., Otu H., et al. A high-fat, ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metab: 2007; 292 6 E1724 E1739
36. Sampath H., Miyazaki M., Dobrzyn A., Ntambi J. M. Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat. J Biol Chem: 2007; 282 4 2483 2493
37. Romestaing C., Piquet M. A., Bedu E., et al. Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr Metab (Lond): 2007; 4 4
38. Newberry E. P., Xie Y., Kennedy S. M., Luo J., Davidson N. O. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology: 2006; 44 5 1191 1205
39. Pfluger P. T., Herranz D., Velasco-Miguel S., Serrano M., Tschöp M. H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A: 2008; 105 28 9793 9798
40. Singh R., Wang Y., Xiang Y., Tanaka K. E., Gaarde W. A., Czaja M. J. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology: 2009; 49 1 87 96
41. Tetri L. H., Basaranoglu M., Brunt E. M., Yerian L. M., Neuschwander-Tetri B. A. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol: 2008; 295 5 G987 G995
42. Koppe S. W., Elias M., Moseley R. H., Green R. M. Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet. Am J Physiol Gastrointest Liver Physiol: 2009; 297 2 G378 G384
43. Obara N., Fukushima K., Ueno Y., et al. Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J Hepatol: 2010; 53 2 326 334
44. Sekiya M., Yahagi N., Matsuzaka T., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology: 2003; 38 6 1529 1539
45. Baumgardner J. N., Shankar K., Hennings L., Badger T. M., Ronis M. J. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol: 2008; 294 1 G27 G38
46. Denechaud P. D., Bossard P., Lobaccaro J. M., et al. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest: 2008; 118 3 956 964
47. Repa J. J., Liang G., Ou J., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev: 2000; 14 22 2819 2830
48. Horton J. D., Goldstein J. L., Brown M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest: 2002; 109 9 1125 1131
49. Li Y., Xu S., Mihaylova M. M., et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab: 2011; 13 4 376 388
50. Takaishi K., Duplomb L., Wang M. Y., Li J., Unger R. H. Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. Proc Natl Acad Sci U S A: 2004; 101 18 7106 7111
51. Engelking L. J., Kuriyama H., Hammer R. E., et al. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest: 2004; 113 8 1168 1175
52. Shimomura I., Matsuda M., Hammer R. E., Bashmakov Y., Brown M. S., Goldstein J. L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell: 2000; 6 1 77 86
53. Ide T., Shimano H., Yahagi N., et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol: 2004; 6 4 351 357
54. Towle H. C., Kaytor E. N., Shih H. M. Regulation of the expression of lipogenic enzyme genes by carbohydrate. Annu Rev Nutr: 1997; 17 405 433
55. Iizuka K., Horikawa Y. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr J: 2008; 55 4 617 624
56. Dentin R., Benhamed F., Hainault I., et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes: 2006; 55 8 2159 2170
57. Benhamed F., Denechaud P. D., Lemoine M., et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest: 2012; 122 6 2176 2194
58. Aarsland A., Wolfe R. R. Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. J Lipid Res: 1998; 39 6 1280 1286
59. Korchak H. M. Regulation of hepatic lipogenesis. Tufts Folia Med: 1962; 8 134 143
60. Bookout A. L., Jeong Y., Downes M., Yu R. T., Evans R. M., Mangelsdorf D. J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell: 2006; 126 4 789 799
61. Mangelsdorf D. J., Thummel C., Beato M., et al. The nuclear receptor superfamily: the second decade. Cell: 1995; 83 6 835 839
62. Mangelsdorf D. J., Evans R. M. The RXR heterodimers and orphan receptors. Cell: 1995; 83 6 841 850
63. Christodoulides C., Vidal-Puig A. PPARs and adipocyte function. Mol Cell Endocrinol: 2010; 318 1-2 61 68
64. Atherton H. J., Gulston M. K., Bailey N. J., et al. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Mol Syst Biol: 2009; 5 259
65. Le May C., Pineau T., Bigot K., Kohl C., Girard J., Pégorier J. P. Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS Lett: 2000; 475 3 163 166
66. Vu-Dac N., Gervois P., Jakel H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem: 2003; 278 20 17982 17985
67. Schoonjans K., Peinado-Onsurbe J., Lefebvre A. M., et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J: 1996; 15 19 5336 5348
68. Wolfrum C., Borrmann C. M., Borchers T., Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A: 2001; 98 5 2323 2328
69. Martin G., Schoonjans K., Lefebvre A. M., Staels B., Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem: 1997; 272 45 28210 28217
70. Fruchart J. C. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis: 2009; 205 1 1 8
71. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J. C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation: 1998; 98 19 2088 2093
72. Vacca M., Degirolamo C., Mariani-Costantini R., Palasciano G., Moschetta A. Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip Rev Syst Biol Med: 2011; 3 5 562 587
73. Shah A., Rader D. J., Millar J. S. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis: 2010; 210 1 35 40
74. Ip E., Farrell G. C., Robertson G., Hall P., Kirsch R., Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology: 2003; 38 1 123 132
75. Abdelmegeed M. A., Yoo S. H., Henderson L. E., Gonzalez F. J., Woodcroft K. J., Song B. J. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr: 2011; 141 4 603 610
76. Su Q., Baker C., Christian P., et al. Hepatic mitochondrial and ER stress induced by defective PPARα signaling in the pathogenesis of hepatic steatosis. Am J Physiol Endocrinol Metab: 2014; 306 11 E1264 E1273
77. Chan S. M., Sun R. Q., Zeng X. Y., et al. Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes: 2013; 62 6 2095 2105
78. Stienstra R., Mandard S., Patsouris D., Maass C., Kersten S., Müller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology: 2007; 148 6 2753 2763
79. Shiri-Sverdlov R., Wouters K., van Gorp P. J., et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol: 2006; 44 4 732 741
80. Laurin J., Lindor K. D., Crippin J. S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology: 1996; 23 6 1464 1467
81. Fernández-Miranda C., Pérez-Carreras M., Colina F., López-Alonso G., Vargas C., Solís-Herruzo J. A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis: 2008; 40 3 200 205
82. Barish G. D., Narkar V. A., Evans R. M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest: 2006; 116 3 590 597
83. Grimaldi P. A. Regulatory functions of PPARbeta in metabolism: implications for the treatment of metabolic syndrome. Biochim Biophys Acta: 2007; 1771 8 983 990
84. Berger J., Leibowitz M. D., Doebber T. W., et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem: 1999; 274 10 6718 6725
85. Coleman J. D., Prabhu K. S., Thompson J. T., et al. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic Biol Med: 2007; 42 8 1155 1164
86. Wang Y. X., Lee C. H., Tiep S., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell: 2003; 113 2 159 170
87. Roberts L. D., Hassall D. G., Winegar D. A., Haselden J. N., Nicholls A. W., Griffin J. L. Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor delta from Peroxisome proliferator-activated receptor gamma in the ob/ob mouse. Genome Med: 2009; 1 12 115
88. Barroso E., Rodríguez-Calvo R., Serrano-Marco L., et al. The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology: 2011; 152 5 1848 1859
89. Liu S., Hatano B., Zhao M., et al. Role of peroxisome proliferator-activated receptor delta/beta in hepatic metabolic regulation. J Biol Chem: 2011; 286 2 1237 1247
90. Qin X., Xie X., Fan Y., et al. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology: 2008; 48 2 432 441
91. Serrano-Marco L., Barroso E., El Kochairi I., et al. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia: 2012; 55 3 743 751
92. Nagasawa T., Inada Y., Nakano S., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol: 2006; 536 1-2 182 191
93. Vu-Dac N., Chopin-Delannoy S., Gervois P., et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem: 1998; 273 40 25713 25720
94. Tanaka T., Yamamoto J., Iwasaki S., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A: 2003; 100 26 15924 15929
95. Leibowitz M. D., Fiévet C., Hennuyer N., et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett: 2000; 473 3 333 336
96. Oliver W. R. Jr, Shenk J. L., Snaith M. R., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A: 2001; 98 9 5306 5311
97. Wallace J. M., Schwarz M., Coward P., et al. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res: 2005; 46 5 1009 1016
98. Kostadinova R., Montagner A., Gouranton E., et al. GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell Biosci: 2012; 2 1 34
99. Vacca M., Degirolamo C., Massafra V., et al. Nuclear receptors in regenerating liver and hepatocellular carcinoma. Mol Cell Endocrinol: 2013; 368 1-2 108 119
100. Vacca M., D'Amore S., Graziano G., et al. Clustering nuclear receptors in liver regeneration identifies candidate modulators of hepatocyte proliferation and hepatocarcinoma. PLoS ONE: 2014; 9 8 e104449
101. Savage D. B., Tan G. D., Acerini C. L., et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes: 2003; 52 4 910 917
102. Barroso I., Gurnell M., Crowley V. E., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature: 1999; 402 6764 880 883
103. Semple R. K., Chatterjee V. K., O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest: 2006; 116 3 581 589
104. Jeninga E. H., Gurnell M., Kalkhoven E. Functional implications of genetic variation in human PPARgamma. Trends Endocrinol Metab: 2009; 20 8 380 387
105. Gawrieh S., Marion M. C., Komorowski R., et al. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci: 2012; 57 4 952 957
106. Krey G., Braissant O., L'Horset F., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol: 1997; 11 6 779 791
107. Dyson J. K., Anstee Q. M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol: 2014; 5 4 277 286
108. Chao L., Marcus-Samuels B., Mason M. M., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest: 2000; 106 10 1221 1228
109. Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes: 2001; 50 9 2094 2099
110. Collino M., Aragno M., Castiglia S., et al. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol: 2010; 160 8 1892 1902
111. Hevener A. L., Olefsky J. M., Reichart D., et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest: 2007; 117 6 1658 1669
112. Hevener A. L., He W., Barak Y., et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med: 2003; 9 12 1491 1497
113. Norris A. W., Chen L., Fisher S. J., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest: 2003; 112 4 608 618
114. Lee Y. J., Ko E. H., Kim J. E., et al. Nuclear receptor PPARγ-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis. Proc Natl Acad Sci U S A: 2012; 109 34 13656 13661
115. Morán-Salvador E., López-Parra M., García-Alonso V., et al. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J: 2011; 25 8 2538 2550
116. Yu S., Matsusue K., Kashireddy P., et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem: 2003; 278 1 498 505
117. Cheng A. Y., Fantus I. G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ: 2005; 172 2 213 226
118. Finck B. N., Kelly D. P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest: 2006; 116 3 615 622
119. Leone T. C., Lehman J. J., Finck B. N., et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol: 2005; 3 4 e101
120. Estall J. L., Kahn M., Cooper M. P., et al. Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes: 2009; 58 7 1499 1508
121. Purushotham A., Schug T. T., Xu Q., Surapureddi S., Guo X., Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab: 2009; 9 4 327 338
122. Lin J., Yang R., Tarr P. T., et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell: 2005; 120 2 261 273
123. Lelliott C. J., Medina-Gomez G., Petrovic N., et al. Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol: 2006; 4 11 e369
124. Sonoda J., Mehl I. R., Chong L. W., Nofsinger R. R., Evans R. M. PGC-1beta controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc Natl Acad Sci U S A: 2007; 104 12 5223 5228
125. Bellafante E., Murzilli S., Salvatore L., Latorre D., Villani G., Moschetta A. Hepatic-specific activation of peroxisome proliferator-activated receptor γ coactivator-1β protects against steatohepatitis. Hepatology: 2013; 57 4 1343 1356